KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
16.44
+0.83 (5.32%)
Mar 4, 2026, 1:23 PM EST - Market open
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 270 employees as of April 30, 2025. The number of employees increased by 120 or 80.00% compared to the previous year.
Employees
270
Change (1Y)
120
Growth (1Y)
80.00%
Revenue / Employee
$5,281
Profits / Employee
-$752,211
Market Cap
830.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Apr 30, 2025 | 270 | 120 | 80.00% |
| Apr 30, 2024 | 150 | 32 | 27.12% |
| Apr 30, 2023 | 118 | 13 | 12.38% |
| Apr 30, 2022 | 105 | 35 | 50.00% |
| Apr 30, 2021 | 70 | 14 | 25.00% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arvinas | 430 |
| Prime Medicine | 214 |
| Omeros | 202 |
| Kura Oncology | 192 |
| Janux Therapeutics | 109 |
| Annexon | 99 |
| AgomAb Therapeutics NV | 58 |
| Bright Minds Biosciences | 26 |
KALV News
- 6 hours ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 days ago - KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - Business Wire
- 7 days ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 14 days ago - KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline - Business Wire
- 20 days ago - KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - Business Wire
- 20 days ago - KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion - Seeking Alpha
- 4 weeks ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga